Introduction {#S1}
============

Asthma is a complex respiratory disease characterized by hyper-responsiveness of the bronchial muscles, chronic inflammation and reversible narrowing of the airways. It affects approximately 300 million individuals worldwide and its prevalence is expected to increase to 400 million by 2025.^[@R1]^ Asthma is the most common chronic illness in children,^[@R2],[@R3]^ accounting for half a million hospitalizations a year in the United States. In 2007, asthma related health care costs in the US were estimated to be \$56 billion, with the majority attributed to medications and hospitalizations.^[@R4]^ Taken together, asthma has a significant public health impact and steps towards its prevention or better management will decrease the overall disease burden.

β~2~-agonists are the most commonly used drugs for treating asthma.^[@R2]^ The therapeutic effects result from binding to the transmembrane *β*~2~-adrenergic receptor (*β*~2~-AR) located on airway smooth muscle cells to relieve bronchoconstriction. These are available as short-acting β~2~-agonists (SABA; e.g. albuterol) for rescuing acute asthma symptoms or as long-acting β~2~-agonists (LABA; e.g. salmeterol and formoterol) for controlling chronic asthma that is usually administered in combination with an inhaled corticosteroid. The reversibility of airway obstruction in response to these medications, known as bronchodilator response (BDR), may be measured as a change in lung function (forced expiratory volume in one second (FEV~1~)) or as fall in peak expiratory flow rate (PEFR), indicating a down-regulation of *B*~2~-agonist responsivity (tachyphylaxis) with prolonged drug use. Inter-individual variability in response to these drugs have been previously described and research suggests that genetic variants are major contributing factors.^[@R3]^ The identification of genetic loci associated with BDR to β~2~-agonists will help to facilitate personalized asthma treatment regimens.

Pharmacogenetic investigations of BDR have identified a number of genetic associations for this variable drug response. The majority had been candidate gene studies, which reported genetic associations to SNPs and/or haplotypes in the arginase 1 (*ARG1*) locus,^[@R5]^ the β~2~-adrenergic receptor (*ADRB2*) gene,^[@R6]--[@R9]^ the corticotropin-releasing hormone receptor (*CRHR*)-2 locus,^[@R10]^ and the adenylyl cyclase type 9 (*AC9*) gene.^[@R11]^ A recent genome-wide association study (GWAS) of BDR by our group identified a functional variant in the serine-rich 2-like (*SPATS2L*) gene, albeit the mechanism by which it regulates BDR remains unknown.^[@R12]^ In this manuscript, we expand on the previous literature by using a novel approach to identify genetic associations with BDR (defined by a change in lung function) whereby we apply five statistical models in a GWAS of this drug response phenotype to decrease the likelihood of false positive associations. Novel aspects of the current GWAS include use of genetic data from the parents of asthmatics in a family-based test, which is more robust against population stratification, as well as analysis of 11 BDR measures for each subject taken over a four year period in addition to BDR at randomization (taken upon entry into the clinical trial). Moreover, we considered both additive and recessive transmissions of the associated alleles. We then pooled the results from these multiple genome-wide analytical models to identify common genetic association signals to carry forward for replication analysis in additional asthma populations. This manuscript describes the findings of our innovative GWAS of BDR in asthmatic subjects.

Methods {#S2}
=======

Asthma Trial Populations {#S3}
------------------------

The asthma trial populations are summarized in [Table 1](#T1){ref-type="table"} and details are available in the [Supplemental Material](#SD1){ref-type="supplementary-material"}. All patients or their legal guardians consented to each study protocol and ancillary genetic testing. All studies were approved by the respective Institutional Review Boards and/or Ethics Committees of the participating institutions.

### Initial GWAS Population {#S4}

A total of 403 non-Hispanic white asthmatic children and their parents from the Childhood Asthma Management Program (CAMP)^[@R13],[@R14]^ were successfully genotyped on the Illumina HumanHap550v3 BeadChip (San Diego, CA).^[@R15]^ BDR at randomization were conducted for each proband upon entry into the trial following 2 inhalations of albuterol. A total of 11 longitudinal BDR values were measured in a subset of 171 asthmatics randomized to inhaled albuterol therapy as needed over four years of this clinical trial. Genome-wide association analysis included 534,290 autosomal SNPs that had passed quality control metrics (see [Supplemental Material](#SD1){ref-type="supplementary-material"}).

### Primary Replication Populations {#S5}

A total of 1536 SNPs were selected for genotyping, of which 1397 were successful, in three non-Hispanic white adult asthma trials (pooled n=764) using the Illumina GoldenGate Custom Array (Illumina Inc., San Diego, CA). SNP selection criteria are detailed below (**Statistical Methodology**). These replication populations included: 1) the Asthma Trial (AT, n=444)^[@R16],[@R17]^; 2) the Leukotriene modifier or Corticosteroid or Corticosteroid Salmeterol (LOCCS, n=165) trial^[@R18]^; and 3) the Effectiveness of Low Dose Theophylline as Add-on Treatment in Asthma (LODO, n=155) trial.^[@R19]^ BDR at randomization was conducted for each subject upon entry into these clinical trials.

### Secondary Replication Populations {#S6}

A total of 13 SNPs with one-sided p-values \< 0.05 (based on the direction of association in CAMP) in the primary replication analysis were further tested in two additional asthma trials: 1) the Childhood Asthma Research and Education Network (CARE, n=215) and 2) the Asthma Clinical Research Network (ACRN, n=241).^[@R20]^ As these individuals had been genotyped on the Affymetrix Genome-Wide Human SNP Array 6.0 (Santa Clara, CA), imputed data was used that was generated for the HapMap Phase 2 Release 22 SNPs^[@R21]^ by applying the Markov Chain Haplotyping (MaCH) software.^[@R22]^ Finally, eight of these 13 SNPs were further tested in the Genetics of Asthma in Costa Rica Study (GACRS), which were successfully genotyped on the HumanOmniExpress-12v1_A chip.^[@R23]^ BDR at randomization was conducted for each subject upon entry into these clinical trials.

Statistical Methodology {#S7}
-----------------------

The primary outcome measure of all analyses was BDR to the inhaled s~2~-agonist albuterol, which was calculated as the percent change in forced expiratory volume in one second (FEV~1~): BDR=100 × \[(postFEV~1~-preFEV~1~)/preFEV~1~\], where preFEV1 is the lung function before albuterol treatment (baseline) and postFEV1 is the lung function following albuterol treatment. The overall analysis strategy is presented in [Figure 1](#F1){ref-type="fig"}. To compensate for the limited statistical power given the small sample size of the CAMP trial, we used five statistical models to identify the most robust genetic associations: generalized linear model of BDR in 403 probands, using recessive (1) and additive (2) models; mixed model of 11 repeated measures of BDR over four years in 171 individuals randomized to as-needed inhaled β~2~-agonist, using recessive (3) and additive (4) models; and family-based association test (FBAT) of BDR at randomization in 403 CAMP parent-offspring trios (5). All models were adjusted for age, sex, and baseline preFEV~1~ and model 5 was additionally adjusted for height. Each SNP was given a score of 0 to 5 based on the total number of p-values below 0.05 from all five association tests. All SNPs scoring 5 (n = 437) were carried forward for genotyping in the primary replication cohort but those scoring 4 were then ranked according to their p-values from the FBAT analysis as this model is robust against population stratification. No SNPs scoring below 4 were included for replication. All tests using generalized linear (additive and recessive) models were performed in PLINK (<http://pngu.mgh.harvard.edu/purcell/plink/>)^[@R24]^ and included SNPs with minor allele frequencies (MAF) ≥ 0.05. FBAT applied a pedigree-based analysis tool (PBAT) previously described.^[@R25]^ All replication analyses used a single measure of BDR at randomization, with adjustments for age, sex, height and baseline preFEV~1~. Multiple comparisons were adjusted using the Liptak weighted Z method.^[@R26]^ Additional details are available in the [Supplemental Material](#SD1){ref-type="supplementary-material"}.

Expression Quantitative Trait Analysis {#S8}
--------------------------------------

Microarray data from immortalized lymphoblastoid cell lines of 117 asthmatics (non-Hispanic white CAMP subjects), spotted on the Illumina HumanRef8v2 microarray BeadChips, were used to test the correlation of genetic variants with gene expression. These cells were cultured and treated with ethanol (sham) as a control for differential analysis with corticosteroid (dexamethasone) treated cells for a separate pharmacogenetic investigation (unpublished data). The microarray data from the sham arm of this experiment was vst-transformed and quantile normalized using the Lumi package in Bioconductor.^[@R27]^ A cis-expression quantitative trait locus (eQTL) was defined as a SNP that was correlated with the expression of a gene within 50 kb. A trans-eQTL was a SNP correlation with a transcript located more than 50 kb away or on a separate chromosome entirely.

Results {#S9}
=======

The baseline characteristics of all asthma populations including CAMP, the three primary replication trials and the three secondary replication populations are shown in [Table 1](#T1){ref-type="table"}. Whereas the initial GWAS using CAMP consisted of childhood asthmatics, the replication populations included both childhood (CARE and GACRS) and adult asthmatics (pooled AT/LOCCS/LODO and ACRN). It is also notable that the adult asthma populations had fewer males and lower pre-bronchodilator FEV~1~ percent predicted (Pre-BD FEV~1~pp) values, which was previously correlated with higher BDR.^[@R28]^ To compensate for the variability in baseline preFEV~1~ across populations, we adjusted each association test for this variable in addition to accounting for it in our phenotype definition (BDR=100×\[(postFEV~1~-preFEV~1~)/preFEV~1~\]).

Genome-wide analysis in CAMP {#S10}
----------------------------

A plot of the --Log~10~(p-values) against the chromosomal location of each SNP from the family-based association (FBAT) analysis is shown in [Figure 2](#F2){ref-type="fig"}. A quantile-quantile plot of the expected p-values of the FBAT analysis under the null hypothesis and the actual observed p-values illustrates that the majority of p-values were greater than expected by chance, suggesting that the test was conservative \[[Supplemental Figure 1](#SD2){ref-type="supplementary-material"}\]. However, there are several p-values less than what was expected by chance. For example, the lowest p-value was 5.28×10^−7^ for rs8112048 located 3′ of the zinc finger protein 14 (*ZNF14*) gene but this did not meet genome-wide significance. In addition, we noted that many SNPs in previously implicated genes (*ARG1, ADRB2, CRHR-2,* and *AC9)*^[@R5]--[@R11]^ were absent from our GWAS due to differences in genotyping platforms. Of the four markers included in our GWAS (rs1042713 in *ADRB2*, rs4723002 and rs226716 in *CRHR2*, and rs2230739 in *AC9*), nominal association was found for rs1042713 in *ADRB2* (p \< 0.02), which is the most investigated locus for BDR. Finally, the genomic inflation factor estimate was 1.01, demonstrating minimal population stratification.

Replication Analyses {#S11}
--------------------

Data for the 1397 replication SNPs from the three adult asthma trials were pooled for analysis to maximize the statistical power for detecting associations. A total of 13 SNPs replicated in the same direction as the initial GWAS population (CAMP) and were carried forward for analysis in the secondary replication phase ([Table 2](#T2){ref-type="table"}). The intergenic SNP, rs11252394, with a p-value of 0.0099 (beta = 3.1) from the additive model in CAMP, had a one-sided p-value of 1.21×10^−6^ in the primary replication phase, which remained significant following Bonferroni correction for multiple comparisons. However, this SNP did not replicate in the secondary replication phase. Next, nominal association signals (p-values \< 0.05) were derived for an intronic SNP, rs6988229, in the collagen type XXII alpha 1 (*COL22A1*) gene in CAMP (recessive p-value = 0.004, beta = 3.26). This SNP further replicated across all asthma populations except for CARE (Liptak combined p = 8.51E-06). Finally, five additional SNPs showed marginal association (p \< 0.05) in the primary replication and one of the three secondary replication populations: rs166330, rs166332, rs17495520, rs6002674, and rs1522113. The latter marker (additive p-value = 0.014 and beta = 3.23 in CAMP), is located in intron 8 of *CLOCK* and in perfect linkage disequilibrium (correlation coefficient (r^2^) of 1.0 in CAMP) with a non-synonymous variant (rs34897046; Serine208Cysteine (S208C)) in exon 9 of the same gene.^[@R29]^ The top 13 SNPs explain 23.8% of the overall genetic variance in BDR, based on the correlation coefficient for each analysis. This calculation assumed that the genetic contribution of each SNP is independent of the other genetic associations.

Analysis of microarray data from lymphoblastoid cell lines from a subset of CAMP subjects determined that the missense variant in *CLOCK* is associated with variable gene expression of both *CLOCK* (p-value = 0.05) and one of its downstream effectors Period 2 gene (*PER2,* p-value = 0.003) \[[Supplemental Figure 2](#SD3){ref-type="supplementary-material"}\]. Individuals with one mutant allele (CG genotype, n = 20) had greater expression of both *CLOCK* and *PER2* compared to individuals without this minor allele (GG genotype, n = 94). The SNP rs6988229 in the *COL22A1* locus on the other hand did not demonstrate any cis-regulatory effects, however, it is correlated with the expression of multiple other genes (trans-acting effects on gene expression). This includes another member of the G protein-coupled receptor superfamily (*GPR110*). The top five trans-effects of each of the 13 SNPs from [Table 2](#T2){ref-type="table"} are shown in [Supplemental Table 1](#SD1){ref-type="supplementary-material"}. These results did not suggest a regulatory role for the intergenic SNP on chromosome 10 (rs11252394). While these associations with gene expression suggest functional effects of some of our associated polymorphisms, further investigation is necessary to validate their functional effects and the mechanism by which they might regulate BDR.

Discussion {#S12}
==========

This manuscript describes a comprehensive GWAS of treatment response to β~2~-agonists in asthmatics, which identifies novel pharmacogenetic loci associated with clinical response variability. Due to the limited size of the asthma drug trial populations, which is common in pharmacogenetic investigations, we implemented a novel strategy to select SNPs for replication. Specifically, we prioritized SNPs by evaluating p-values from 5 different statistical models, thereby taking advantage of the longitudinal nature of the phenotypic data, the entire sample at randomization, as well as the genotype data from the parents. SNPs with the lowest p-values (\< 0.05) across all five statistical models were judged to represent the most robust associations, followed by SNPs yielding p-values \< 0.05 in four of the five analyses. The latter were prioritized by FBAT p-values for replication analysis. A total of 1397 were successfully genotyped and tested for replication in three independent clinical trials. The top 13 replicated SNPs were subsequently tested for association with BDR in three secondary asthma populations ([Table 2](#T2){ref-type="table"}). While only one intergenic SNP significantly replicated in the primary phase, six SNPs provided nominal p-values \< 0.05 in both the primary replication phase and in one or more of the secondary replication populations, including intronic SNPs in the *COL22A1* and *CLOCK* genes.

The use of five statistical models in our initial GWAS is an innovative approach for identifying genetic associations for BDR in asthma. As each statistical model has unique strengths and weaknesses, our rationale for ranking SNPs for replication based on p-values from all five models was to identify the most robust associations (i.e. those most likely to replicate and represent true pharmacogenetic associations). For example, population-based tests are more powerful to detect associations by including more individuals than the number of informative families used in the FBAT, but the former is more vulnerable to population stratification. Thus, FBAT allows us to confirm SNP associations that are not influenced by population stratification. In addition, we were able to take advantage of the longitudinal BDR data recorded at 11 time points over the four year clinical trial for a subset of our population to confirm associations that are repeatable within individuals over time. Moreover, we opted to include a recessive model because while an additive genetic model can easily identify dominant transmissions, it does not identify recessive transmissions as easily. We believe that this novel approach reduced the likelihood of false-positive association signals.

The strongest association signal that significantly replicated in the primary replication phase, albeit not associated across the secondary replication populations, was an intergenic SNP rs11252394 (Liptak p-value = 1.98E-07). Despite it being not proximal to a gene within 50 kb, a closer look at this genomic region revealed several excellent biological candidates within 2.5 Mb including Protein Kinase C theta (*PRKCQ*), inter-leukin receptors (*IL15RA*, *IL2RA*) and Krüppel-like factor 6 (*KLF6*). All four genes have been previously reported to regulate pulmonary inflammation using *in vitro* cellular and murine models. In fact, a *PRKCQ* antagonist was investigated by Wyeth Research as a novel treatment for asthma given the role of this gene in airway inflammation and hyper-responsiveness.^[@R30]--[@R32]^ Inhibition of *IL15RA* and *IL2RA* in mice demonstrated decreased lung inflammation.^[@R33],[@R34]^ Finally, blocking of *KLF6 in vitro* decreased Transforming Growth Factor β (TGFβ) production that is correlated with airway remodeling and asthma development.^[@R35]^ While rs11252394 is not known to regulate the expression of any of these genes, nor is it known to be in LD with SNPs within these loci, further investigation is warranted to identify the causative variant, if any, in this genomic region which may underlie this association signal.

Another association signal that replicated, albeit only marginally, in the primary replication phase and across two of the secondary replication trials, was an intronic SNP (rs6988229) in the *COL22A1* gene. Little is known about this gene other than it encodes a protein that acts as a cell adhesion ligand for skin epithelial cells and fibroblasts, further investigations are necessary to determine how genetic variants at this locus might influence BDR. Cis-eQTL analysis indicates that this SNP does not regulate expression of the *COL22A1* transcript (p= 0.86). However, this SNP is significantly correlated with the expression of multiple other genes \[[Supplemental Table 1](#SD1){ref-type="supplementary-material"}\]. This includes another member of G protein-coupled receptor superfamily (*GPR110*), to which the β2-adrenergic receptor also belongs, which is known to regulate smooth muscle contractions and relaxations.^[@R36]^ Multiple splice variants of this gene, like many other members of this large gene family, has been shown to be expressed at significantly higher levels in airway smooth muscle cells.^[@R37]^

While the polymorphism in the *CLOCK* gene (rs1522113) was only marginally associated with BDR at randomization in CAMP using the additive model (p-value = 0.014), and nominally replicated in AT/LOCCS/LODO and CARE, it is an excellent biological candidate for regulating bronchodilator response in asthmatics. Previous studies suggest that *CLOCK* expression and β~2~-agonists affect the expression of circadian rhythm genes, which regulate asthma symptoms. Embryonic fibroblast cells from mice homozygous for mutant *CLOCK* expressed circadian rhythm genes in a non-cyclic manner, a phenotype that was rescued by ectopic expression of *CLOCK*.^[@R38]^ DeBruyne et al. reported that the circadian rhythm in peripheral tissues such as the liver and lung are also regulated by *CLOCK*.^[@R39]^ CLOCK binds to the E-box enhancer located 5′ of circadian genes such as the Periods (*PER*) 1, 2, and 3 to regulate their expression.^[@R40]^β~2-~agonists have also been shown to induce the expression of human period 1 (*hPER1*) gene in bronchial epithelial BEAS-2B cells.^[@R41]^ Furthermore, the administration of β~2~-agonists, particularly long-acting, reduces nocturnal asthma.^[@R42],[@R43]^β~2~-agonists have also been shown to regulate the expression of these circadian rhythm genes through the phosphorylation of cAMP responsive element binding (CREB) protein which bind to CRE 5′ of these genes.^[@R40]^ The role of the circadian rhythm in asthma is apparent in that the narrowing of the airways are more severe between midnight and early morning hours.^[@R44]^ In addition, nocturnal asthma exacerbations are commonly experienced between 4 AM and 8 AM,^[@R43]^ which may be the combined effect of the circadian clock and the diminishing effect of asthma medications throughout the night.

In addition to a genetic association between rs1522113 and BDR in asthma, we determined that this intronic SNP is in perfect linkage disequilibrium with a missense variant in exon 9 (rs34897046; S208C), which is predicted to result in the loss of a (Serine) phosphorylation site.^[@R45]^ This coding SNP is predicted to be "deleterious" by SIFT (Sorting Intolerant From Tolerant)^[@R46]^ or "possibly damaging" by PolyPhen2.^[@R47]^ Finally, analysis of microarray data from lymphoblastoid cell lines of CAMP subjects indicates a marginal association between the mutant allele (208C) and increased expression of *CLOCK* (p value = 0.054), as well as increased expression of a downstream circadian rhythm gene Period 2 (*PER2,* p value = 0.003) \[[Supplemental Figure 2](#SD3){ref-type="supplementary-material"}\]. While this suggests that the associated polymorphism in *CLOCK* may be functional, further experiments are necessary to investigate the regulatory potential of this variant in the *CLOCK* pathway and the mechanism by which it modulates BDR.

While this manuscript represents a comprehensive GWAS of BDR response in asthmatics aimed at identifying the most robust genetic associations for replication in additional asthma trials, there were several limitations. First, our initial GWAS used the phenotype of acute response to a short-acting β~2~-agonist (BDR at randomization) that was taken in all CAMP probands at the start of the study as well as repeated measures of BDR in a subset of the CAMP probands who were randomized to β~2~-agonist as needed over the four years of the trial. For the replication cohorts, however, we only used BDR measured upon entry into the respective studies as our replication samples did not have longitudinal data. Therefore, our replication results may not identify BDR associations in asthma patients taking β~2~-agonist over long periods of time. Second, the mean pre-bronchodilator FEV~1~ percent predicted values varied across the asthma populations ([Table 1](#T1){ref-type="table"}). Specifically, those for all childhood asthma trials (CAMP, CARE and GACRS) were noticeably higher than those of adult asthma trials (AT, LOCCS, LODO and ACRN), which was expected. However, pre-bronchodilator FEV~1~ was adjusted for in our definition of BDR as well in all statistical analyses by including it as a covariate. Finally, baseline medications and recruitment criteria varied across some of the populations. For example, the LOCCS trial had completed a run-in period of 4--6 weeks during which they were administered an inhaled corticosteroid that might have improved their lung function, resulting in reduced BDR. Finally, all participants of the AT trial had a minimum BDR of 15% or greater. We addressed these differences across our trial populations in the pooled analysis of AT/LOCCS/LODO by coding each trial differently. Some of the trials (CAMP, AT, LODO, GACRS) had wash-out periods during which they were taken off their regular asthma therapies but were permitted to use rescue medications as needed. Others such as CARE and ACRN had no wash-out periods. Thus, differences in medical histories may have influenced BDR. However, we believe that these differences further demonstrate the generalizability of our association results.

Although the aim of this GWAS was to identify novel loci for BDR, we noted that this study does not replicate all of the prior associated SNPs.^[@R5]--[@R11]^ These results were expected as it is unusual for all of the candidate genes to be significant in any one replication population. For some of these previously associated loci, the genetic effect sizes were very modest, making these genetic variants more difficult to identify. Power simulations, based on our sample sizes (n = 403, 764, and 1,048) and the number of statistical tests, estimated that we had sufficient power (\>90%) to identify common SNPs (MAF \> 0.1) with effect estimates of 3 percent or greater. In addition, there was not always adequate LD coverage for some of the SNPs that were previously identified at candidate genes. Therefore, it was difficult to assess these genetic associations in our CAMP samples. Specifically, additional variants were genotyped in earlier studies using custom platforms that were not included on the Illumina HapMap550K Beadchip array used for the current GWAS. For example, none of the previously associated SNPs in *ARGI* were tested in the current GWAS. In fact, only four of the dozen SNPs previously implicated in the remaining three genes (*ADRB2*, *CRHR2* and *AC9)* were directly tested in our GWAS. However, these did not yield high ranking scores for replication because we had selected SNPs based on p-values across five different statistical models. Furthermore, some of the earlier studies had reported a haplotype effect that was not tested in our study. Finally, our GWAS did not replicate the findings of the previous BDR GWAS, which reported association with *SPATS2L*.^[@R12]^ A major difference in the current study is the combined analysis of longitudinal BDR measures as well family-based data in addition to BDR at randomization using five statistical models, while the previous GWAS applied only one test of BDR at randomization.

Using a novel genome-wide association analysis method for investigating BDR in asthma, we have identified several genetic loci for further investigation. Among these findings is an intergenic SNP, rs11252394, that is located near multiple genes previously correlated with lung inflammation and therefore, are potential regulators of asthma. Other potentially interesting associations that were marginally associated with our drug response phenotype across multiple trials were intronic SNPs within the *COL22A1* and *CLOCK* loci. While microarray data indicate potential cis- or trans-effects of these SNPs, further investigation is merited to determine their biological significance and potential roles in modulating bronchodilator response to β~2~-agonists.
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![An overview of the genome-wide analyses methods and replication strategies used. The initial GWAS in CAMP applied five statistical models (linear regression of BDR at randomization in 403 asthmatics using additive and recessive models, longitudinal mixed models of 11 repeated BDR measures in 171 probands using additive and recessive models, and a family-based association test of BDR at randomization in 403 trios). A total of 1536 SNPs providing p-values \< 0.05 from five or four of these models (the latter rankd by FBAT p-values) were selected for genotyping and replication in LOCCS/LODO/AT (n=764). The 13 replicated SNPs (one sided p-values \< 0.05) were further tested in ACRN, CARE and GACRS.](nihms442409f1){#F1}

![The distribution of BDR at randomization across all asthma trial populations. BDR is defined as a percent change in lung function (FEV~1~) in response to inhaled albuterol across all asthma trial populations.](nihms442409f2){#F2}

![Manhattan plot of --Log~10~(p-value) for the FBAT analysis of BDR using 403 parent-offspring trios with 534,290 SNPs. Similar plots were generated for the other four statistical models. The analysis was adjusted for age, gender, height, and baseline preFEV~1~.](nihms442409f3){#F3}

###### 

Baseline Characteristics of Participants in the Asthma Populations used in this Analysis.

                                                                      CAMP         CAMP (Placebo)   AT             LOCCS                LODO          AT/LOCCS/LODO   CARE          ACRN          GACRS
  ------------------------------------------------------------------- ------------ ---------------- -------------- -------------------- ------------- --------------- ------------- ------------- -------------
  Age, mean (sd)                                                      8.8 (2.1)    8.7 (2.1)        32.4 (13.6)    34.4 (15.3)          42.9 (14.7)   34.9 (14.8)     10.6 (2.9)    31.7 (42.2)   9.0 (1.8)
   Range                                                              5.2--13.2    5.2 -- 13.2      12.0 -- 80     7 -- 71              15 -- 76      7 -- 80         6--17.8       12.4--63.7    6.0--14.2
  Gender, n(%)                                                                                                                                                                                    
   male                                                               254 (63)     109 (60)         222 (50.0)     58 (35.2)            39 (25.2)     319 (41.8)      132 (61.4)    100 (41.49)   351 (59.3)
  Wash-out prior to BDR test[\*](#TFN1){ref-type="table-fn"}, weeks   4            4                6              4--6 (fluticasone)   2             2--6            0--4          0--6          4
  Albuterol puffs (90ug/puff)                                         2            2                2              2                    2             2               4             2--4          2
  pre-BD FEV~1\ pp,~ mean (sd)                                        93.4(14.0)   94.7(13.3)       61.5 (6.8)     84.3 (12.3)          78.8 (17.7)   69.8 (14.7)     99.3 (12.6)   85.9 (13.5)   99.8 (17.2)
  BDR, mean (sd)                                                      11(10)       12 (11)          40.15 (20.9)   6.4 (6.1)            9.7 (11.1)    26.7 (23.2)     9.5 (8.4)     11.6 (21.8)   5.7 (9.2)

Subjects were permitted to use rescue medications as needed during the wash-out period

###### 

Summary of GWAS and replication analyses in all asthma clinical trials.

  ------------ ---- --- ------ ----------- ----------- ------------------------------------------- ---------- -------- -------- -------- ----------
  rs11252394   10   A   0.08               Additive    0.0099[b](#TFN4){ref-type="table-fn"} (+)   1.21E-06   0.4173   0.3472   \-       1.98E-07
  rs6988229    8    T   0.20   *COL22A1*   Recessive   0.0004[c](#TFN5){ref-type="table-fn"} (+)   0.0050     0.0505   0.9283   0.0139   8.51E-06
  rs9552679    13   C   0.26               Additive    0.0007[d](#TFN6){ref-type="table-fn"} (−)   0.0004     0.7884   0.4410   \-       3.02E-05
  rs1663330    14   G   0.33               Additive    0.0020[b](#TFN4){ref-type="table-fn"} (+)   0.0028     0.0234   0.7544   \-       4.54E-05
  rs1663332    14   T   0.37               Additive    0.0028[b](#TFN4){ref-type="table-fn"}(+)    0.0006     0.0374   0.6874   0.3595   8.07E-05
  rs17495520   5    T   0.14               Additive    0.038[b](#TFN4){ref-type="table-fn"} (+)    0.0110     0.0030   0.3587   \-       0.0003
  rs10511905   9    G   0.22               Additive    0.006[a](#TFN3){ref-type="table-fn"} (−)    0.0087     0.1388   0.3149   \-       0.0003
  rs518350     22   T   0.12               Recessive   0.0065[e](#TFN7){ref-type="table-fn"} (+)   0.0010     0.4987   0.2090   0.3334   2.70E-04
  rs17701271   4    A   0.22               Recessive   0.004[c](#TFN5){ref-type="table-fn"} (+)    0.0026     0.1371   0.8756   0.2031   0.0003
  rs6002674    22   C   0.15               Recessive   0.0012[e](#TFN7){ref-type="table-fn"} (−)   0.0040     0.9808   0.0310   0.5675   0.0027
  rs1419555    7    T   0.37               Additive    0.0043[d](#TFN6){ref-type="table-fn"} (+)   0.0060     0.7723   0.6879   0.4932   0.0068
  rs1423515    5    A   0.05               Additive    0.027[b](#TFN4){ref-type="table-fn"} (+)    0.0400     0.4104   0.4710   \-       0.0089
  rs1522113    4    A   0.05   *CLOCK*     Additive    0.014[b](#TFN4){ref-type="table-fn"} (+)    0.0037     0.9260   0.0427   0.8633   0.0177
  ------------ ---- --- ------ ----------- ----------- ------------------------------------------- ---------- -------- -------- -------- ----------

Association results for 13 replicated SNPs (p-values \< 0.05) from the primary replication phase only are shown, sorted by Liptak Combined P-values. The p-values presented for CAMP are 2-sided while p-values for the replication populations are 1-sided, based on the direction of association (denoted as + or −) relative to the CAMP analysis. MAF: minor allele frequency in CAMP.

Lowest p-value is with the family-based association test (FBAT)

Lowest p-value is with the additive generalized linear model

Lowest p-value is with the recessive generalized linear model

Lowest p-value is with the additive longitudinal analysis

Lowest p-value is with the recessive longitudinal analysis

[^1]: These authors contributed equally to this manuscript
